The onlinevideoseems to promise everything an arthritis patient could want.
The six-minute segment mimics a morning talk show, using a polished TV host to interview guests around a coffee table. Dr. Adam Pourcho extols the benefits of stem cells and regenerative medicine for healing joints without surgery. Pourcho, a sports medicine specialist, says he has used platelet injections to treat his own knee pain, as well as a tendon injury in his elbow. Extending his arm, he says, Its completely healed.
Brendan Hyland, a gym teacher and track coach, describes withstanding intense heel pain for 18 months before seeing Pourcho. Four months after the injections, he says, he was pain-free and has since gone on a 40-mile hike.
I dont have any pain that stops me from doing anything I want, Hyland says.
Critics suggest the hospitals are exploiting desperate patients and profiting from trendy but unproven treatments.
The videos cheerleading tone mimics theinfomercialsused to promote stem cell clinics, several of which have recently gotten into hot water with federal regulators, saidDr. Paul Knoepfler, a professor of cell biology and human anatomy at the University of California-Davis School of Medicine. But the marketing video wasnt filmed by a little-known operator.
It was sponsored bySwedishMedical Center, the largest nonprofit health provider in the Seattle area.
Swedish is one of a growing number ofrespected hospitalsandhealth systems including theMayo Clinic, theCleveland Clinicand theUniversity of Miami that have entered the lucrative business ofstem cellsandrelated therapies, including platelet injections. Typical treatments involveinjecting patients joints with their own fatorbone marrowcells, or with extracts ofplatelets, the cell fragments known for their role in clotting blood. Many patients seek out regenerative medicine to stave off surgery, even though theevidencesupporting these experimental therapies isthin at best, Knoepfler said.
Hospitals say theyre providing options to patients who have exhausted standard treatments. But critics suggest the hospitals are exploiting desperate patients and profiting from trendybut unproventreatments.
TheFood and Drug Administrationis attempting to shut down clinics that hawk unapproved stem cell therapies, which have been linked toseveral cases of blindnessand atleast 12 serious infections. Although doctors usually need preapproval to treat patients with human cells, the FDA has carved out ahandful of exceptions,as long as the cells meet certain criteria, said Barbara Binzak Blumenfeld, an attorney who specializes in food and drug law at Buchanan Ingersoll & Rooney in Washington.
Hospitals like Mayo are careful to follow these criteria, to avoid running afoul of the FDA, said Dr. Shane Shapiro, program director for the Regenerative Medicine Therapeutics Suites at Mayo Clinics campus in Florida.
While hospital-based stem cell treatments may be legal, theres nostrong evidencethey work, said Leigh Turner, an associate professor at the University of Minnesotas Center for Bioethics who has published a series of articles describing the size and dynamics of thestem cell market.
FDA approval isnt needed and physicians can claim they arent violating federal regulations, Turner said. But just because something is legal doesnt make it ethical.
For doctors and hospitals, stem cells are easy money, Turner said. Patients typically paymore than $700a treatment for platelets and up to$5,000for fat and bone marrow injections. As a bonus, doctors dont have to wrangle with insurance companies, which view the procedures asexperimentaland largelydont cover them.
For doctors and hospitals, stem cells are easy money.
Its an out-of-pocket, cash-on-the-barrel economy, Turner said. Across the country, clinicians at elite medical facilities are lining their pockets by providingexpensive placebos.
Some patient advocates worry that hospitals are more interested in capturing a slice of the stem-cell market than in proving their treatments actually work.
Its lucrative. Its easy to do. All these reputable institutions, they dont want to miss out on the business, said Dr. James Rickert, president of the Society for Patient Centered Orthopedics, which advocates for high-quality care. It preys on peoples desperation.
In a joint statement, Pourcho and Swedish defended the online video.
The terminology was kept simple and with analogies that the lay person would understand, according to the statement. As with any treatment that we provide, we encourage patients to research and consider all potential treatment options before deciding on what is best for them.
But Knoepfler said the guests on the video make several unbelievable claims.
At one point, Dr. Pourcho says thatplatelets release growth factorsthat tell the brain which types of stem cells to send to the site of an injury. According to Pourcho, these instructions make sure that tissues are repaired with the appropriate type of cell, and so you dont get, say, eyeball in your hand.
Knoepfler, who has studied stem cell biology for two decades, said he has never heard of any possibility of growing eyeball or other random tissues in your hand. Knoepfler, who wrote about the video in February on his blog,The Niche, said, Theres no way that the adult brain could send that kind of stem cells anywhere in the body.
The marketing video debuted in July on KING-TV, a Seattle station, as part of a local lifestyles show called New Day Northwest. Although much of the show is produced by the KING 5 news team, some segments like Pourchos interview are sponsored by local advertisers, said Jim Rose, president and general manager of KING 5 Media Group.
After being contacted by KHN, Rose asked Swedish to remove the video from YouTube because it wasnt labeled as sponsored content. Omitting that label could allow the video to be confused with news programming. The video now appears only on the KING-TV website, where Swedish is labeled as the sponsor.
The goal is to clearly inform viewers of paid content so they can distinguish editorial and news content from paid material, Rose said. We value the publics trust.
Federal authorities have recently begun cracking down on doctors who make unproven claims or sell unapproved stem cell products.
In October, theFederal Trade Commissionfined stem cell clinics millions of dollars for deceptive advertising, noting that the companies claimed to be able to treat or cure autism, Parkinsons disease and other serious diseases.
In a recent interview Scott Gottlieb, the FDA commissioner, said the agency will continue to go after what he called bad actors.
Withmore than 700stem cell clinics in operation, the FDA is first targeting those posing the biggest threat, such as doctors who inject stem cells directly into the eye or brain.
There are clearly bad actors who are well over the line and who are creating significant risks for patients, Gottlieb said.
Federal authorities have recently begun cracking down on doctors who make unproven claims or sell unapproved stem cell products.
Gottlieb, set to leave office April 5, said hes also concerned about the financial exploitation of patients in pain.
Theres economic harm here, where products are being promoted that arent providing any proven benefits and where patients are paying out-of-pocket, Gottlieb said.
Dr. Peter Marks, director of the FDAs Center for Biologics Evaluation and Research, said there is a broad spectrum of stem cell providers, ranging from university scientists leading rigorous clinical trials to doctors who promise stem cells are for just about anything. Hospitals operate somewhere in the middle, Marks said.
The good news is that theyre somewhat closer to the most rigorous academics, he said.
The Mayo Clinics regenerative medicine program, for example, focuses conditions such asarthritis, where injections pose few serious risks, even if thats not yet the standard of care, Shapiro said.
Rickert said its easy to see why hospitals are eager to get in the game.
The market for arthritis treatment is huge and growing. At least30 million Americanshave the most common form of arthritis, with diagnoses expected to soar as the population ages. Platelet injections for arthritis generatedmore than $93 millionin revenue in 2015, according to an article last year in The Journal of Knee Surgery.
We have patients in our offices demanding these treatments, Shapiro said. If they dont get them from us, they will get them somewhere else.
Doctors at the Mayo Clinic try to provide stem cell treatments and similar therapies responsibly, Shapiro said. Ina paper published this year,Shapiro described the hospitals consultation service, in which doctors explain patients options and clear up misconceptions about what stem cells and other injections can do. Doctors can refer patients to treatment or clinical trials.
Most of the patients do not get a regenerative [stem cell] procedure, Shapiro said. They dont get it because after we have a frank conversation, they decide, Maybe its not for me.
Although some hospitals boast of high success rates for their stem cell procedures,published researchoften paints a different story.
TheMayo Clinic websitesays that 40 to 70% of patients find some level of pain relief. Atlanta-basedEmory Healthcareclaims that 75 to 80% of patients have had significant pain relief and improved function. In the Swedish video, Pourcho claims we can treat really any tendon or any joint with PRP.
The strongest evidence for PRP is in pain relief for arthritic knees and tennis elbow, where it appears to be safe and perhaps helpful, said Dr. Nicolas Piuzzi, an orthopedic surgeon at the Cleveland Clinic.
But PRP hasnt been proven to help every part of the body, he said.
PRP has been linked to serious complications when injected to treatpatellar tendinitis,an injury to the tendon connecting the kneecap to the shinbone. In a 2013 paper, researchers described the cases of three patients whose pain got dramatically worse after PRP injections. One patient lost bone and underwent surgery to repair the damage.
People will say, If you inject PRP, you will return to sports faster, said Dr. Freddie Fu, chairman of orthopedic surgery at the University of Pittsburgh Medical Center. But that hasnt been proven.
A2017 studyof PRP found it relieved knee pain slightly better than injections of hyaluronic acid. But thats nothing to brag about, Rickert said, given thathyaluronic acid therapy doesnt work, either. While some PRP studies have shown morepositive results, Rickert notes that most were so small orpoorly designedthat theirresults arent reliable.
In its 2013 guidelines for knee arthritis, theAmerican Academy of Orthopaedic Surgeonssaid it is unable to recommend for or against PRP.
PRP is sort of a buyer beware situation, said Dr. William Li, president and CEO of the Angiogenesis Foundation, whose research focuses on blood vessel formation. Its the poor mans approach to biotechnology.
Tests of other stem cell injections also have failed to live up to expectations.
Shapiro published a rigorously designed study last year inCartilage, a medical journal, that found bone marrow injections were no better at relieving knee pain than saltwater injections. Rickert noted that patients who are in pain often get relief from placebos. The more invasive the procedure, the stronger the placebo effect, he said, perhaps because patients become invested in the idea that an intervention will really help. Even saltwater injections help 70% of patients, Fu said.
A 2016 review in theJournal of Bone and JointSurgery concluded that the value and effective use of cell therapy in orthopaedics remain unclear. The following year, a review in theBritish Journal of Sports Medicineconcluded, We do not recommend stem cell therapy for knee arthritis.
Shapiro said hospitals and health plans are right to be cautious.
Many patients have trouble sorting through the hype.
The insurance companies dont pay for fat grafting or bone-marrow aspiration, and rightly so, Shapiro said. Thats because we dont have enough evidence.
Rickert, an orthopedist in Bedford, Ind., said fat, bone marrow and platelet injections should be offered only through clinical trials, which carefully evaluate experimental treatments. Patients shouldnt be charged for these services until theyve been tested and shown to work.
Orthopedists surgeons who specialize in bones and muscles have a history of performing unproven procedures, includingspinal fusion, surgery forrotator cuff diseaseandarthroscopyfor worn-out knees, Turner said. Recently, studies have shown them to be no more effective than placebos.
Some argue that joint injections shouldnt be marketed as stem cell treatments at all.
Piuzzi said he prefers to call the injections orthobiologics,noting that platelets are not even cells, let alone stem cells. The number of stem cells in fat and bone marrow injections is extremely small, he said. In fat tissue, only about 1 in 2,000 cells is a stem cell, according to a March paper inThe Bone & Joint Journal. Stem cells are even rarer in bone marrow, where 1 in 10,000 to 20,000 cells is a stem cell.
Patients are attracted to regenerative medicine because they assume it will regrow their lost cartilage, Piuzzi said. Theres no solid evidence that the commercial injections used today spur tissue growth, Piuzzi said. Although doctors hope that platelets will release anti-inflammatory substances, which could theoretically help calm an inflamed joint, they dont know why some patients who receive platelet injections feel better, but others dont.
So, it comes as no surprise that many patients have trouble sorting through the hype.
Florida resident Kathy Walsh, 61, said she wasted nearly $10,000 on stem cell and platelet injections at a Miami clinic, hoping to avoid knee replacement surgery.
When Walsh heard about a doctor in Miami claiming to regenerate knee cartilage with stem cells, it seemed like an answer to a prayer, said Walsh, of Stuart, Fla. Youre so much in pain and so frustrated that you cling to every bit of hope you can get, even if it does cost you a lot of money.
The injections eased her pain for only a few months. Eventually, she had both knees replaced. She has been nearly pain-free ever since. My only regret, she said, is that I wasted so much time and money.
KaiserHealthNewsis an editorially independent program of the Henry J.KaiserFamily Foundation, a nonprofit, nonpartisanhealthpolicy research and communication organization not affiliated withKaiserPermanente. You can view the original report on itswebsite.
Read this article:
Why expensive, unproven stem cell treatments are a new ...
- International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- CSC news links 2010-05-01 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- CSC news links 2010-05-01 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]
- Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]